

Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3078 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Office of Extramural Research; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Peer Review Oversight Group (PROG) on February 13-14, 1997, in the Rockledge II Centre, 6701 Rockledge Drive, Bethesda, Maryland 20817. The meeting will be held from 8:30 a.m. to 5 p.m. on February 13 and from 8:30 a.m. to 12 p.m. on February 14. The meeting is open to the public, with attendance limited to space available.

Topics for discussion include: NIH extramural electronic reinvention activities, the rating of grant applications, the integration of Neuroscience Reviews, and the review of multiple mechanisms within one review group.

The meeting agenda and roster of committee members are available on the World Wide Web via the NIH Home Page (<http://www.nih.gov.grants/>) or from Dr. Peggy McCardle, Executive Secretary, PROG, and Special Assistant to the Deputy Director for Extramural Research, OD, NIH, Building 1, Room 150, Bethesda, Maryland 20892, (301) 402-2246. Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations, should contact Dr. McCardle by February 7, 1997.

This meeting is being published less than 15 days prior to the meeting due to the urgent need to proceed with the meeting as scheduled in order to address these issues in a timely manner.

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3079 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Particle-Medicated Gene Delivery DNA Vaccines Against Dengue and Other Flavivirus Infections

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in U.S. Patent No. 5,494,671, issued February 27, 1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 1991), entitled "C-Terminally Truncated Dengue and Japanese Encephalitis Virus Envelope Proteins"; U.S. Patent Application Serial No. 08/250,802, filed May 27, 1994, entitled "Chimeric and/or Growth Restricted Flaviviruses" and related foreign patent applications to Auragen, Inc./Geniva, Inc. of Middleton, WI. The patent rights in these inventions have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to particle-mediated gene delivery DNA vaccines against Dengue and other flavivirus infections. This license will not include live virus, killed virus, or protein-based vaccines. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent describes the use of C-terminally truncated flavivirus envelope proteins in vaccines against flavivirus infections and also relates to recombinant viruses which encode the truncated protein. The patent applications are directed to recombinant, modified or viable chimeric flaviviruses for use in vaccine preparations against flavivirus infections. This technology further provides for a baculovirus having a recombinant dengue cDNA sequence which encodes dengue proteins and for a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes Japanese B encephalitis proteins. The applications also relate to vaccines produced from recombinant DNA.

ADDRESSES: Requests for a copy of the issued patent, patent application, inquiries, comments, and other materials relating to the contemplated license should be directed to: Gloria H. Richmond, Patent Advisor, Office of Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7057 ext 268; Facsimile: (301) 402-0220; E-mail: Gloria.Richmond@NIH.GOV. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application. Applications for a non-exclusive or exclusive license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before April 8, 1997 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-3080 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Vaccines for Dengue and Other Flaviviruses

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in U.S. Patent No. 5,494,671, issued February 27, 1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 1991), entitled "C-Terminally Truncated Dengue and Japanese Encephalitis Virus Envelope Proteins" to Hawaii Biotechnology Group, Inc. of Aiea, Hawaii. The patent rights in this invention have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the field of subunit vaccines against Dengue and Japanese Encephalitis produced in animal cells. This license will not include live virus, killed virus or DNA-based vaccines or the use of vaccinia virus as a vector, or immunogen. This prospective exclusive license may be granted unless within 60 days from the

date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent describes the use of C-terminally truncated flavivirus envelope proteins in vaccines against flavivirus infections. The invention also relates to recombinant viruses which encode the truncated protein and to host cells infected therewith.

ADDRESSES: Requests for a copy of this issued patent, inquiries, comments, and other materials relating to the contemplated license should be directed to: Gloria H. Richmond, Patent Advisor, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7057 ext 268; Facsimile: (301) 402-0220; E-mail: Gloria.Richmond@NIH.GOV. Applications for a non-exclusive or exclusive license filed in a response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before April 8, 1997 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-3081 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Proposed Agency Information Collection Activities; Comment Request

AGENCY: Bureau of Indian Affairs.

ACTION: Notice.

SUMMARY: This notice announces that the Information Collection Request for Documented Petitions for Federal Acknowledgment as an Indian Tribe requires renewal. Before submitting a request for reinstatement, without change, of a previously approved collection for which approval has expired to the Office of Management and Budget (OMB), the Department of the Interior is soliciting comments on this information collection, as required

by the Paperwork Reduction Act of 1995, Public Law 104-13, 44 U.S.C. 3506(c)(2)(A).

DATES: Written comments must be submitted on or before April 8, 1997.

ADDRESSES: Direct all written comments to Holly Reckord, Bureau of Indian Affairs, Department of the Interior, 1849 C Street, NW, MS-4603, Washington, D.C. 20240.

All written comments will be available for public inspection in Room 4603 of the Main Interior Building, 1849 C Street, NW, Washington, D.C. from 9:00 a.m. until 3:00 p.m., Monday through Friday, excluding legal holidays.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or copies of the information collection instructions should be directed to Holly Reckord, Bureau of Indian Affairs, Department of the Interior, 1849 C Street, NW, MS-4603, Washington, D.C. 20240, and 202/208-3592.

SUPPLEMENTARY INFORMATION:

1. Abstract

The information collection is needed to establish whether a petitioning group has the characteristics necessary to be acknowledged as having a government-to-government relationship with the United States.

2. Method of Collection

The acknowledgment regulations at 25 CFR Part 83 contain seven criteria (§ 83.7) which unrecognized groups seeking Federal acknowledgment as Indian tribes must demonstrate that they meet. Information collected from petitioning groups under these regulations provides anthropological, genealogical and historical data used by the Assistant Secretary—Indian Affairs to establish whether a petitioning group has the characteristics necessary to be acknowledged as having a government-to-government relationship with the United States.

3. Data

Title: Collection of Information for Federal Acknowledgment Under 25 CFR Part 83.

OMB Number: 1076-0104.

Expiration Date: January 31, 1997.

Type of Review: Reinstatement of approved collection.

Affected Entities: Groups petitioning for Federal acknowledgment as Indian tribes.

Estimated Number of Petitioners: 10.

Estimated Time per Petition: 2,175 hours.

Estimated Total Annual Burden Hours: 21,750.

Estimated Annual Costs: \$870,000 (2,175 hours × \$40.00 per hour).

4. Request for Comments

The Department of the Interior invites comment on:

(a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(b) The accuracy of the Agency's estimate of the burden (including hours and cost) of the proposed collection of information, including the validity of the methodology and assumptions used;

(c) Ways to enhance the quality, utility, and clarity of the information to be collected; and

(d) Ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other collection techniques or other forms of information technology.

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information, to search data sources, to complete and review the collection of information; and to transmit or otherwise disclose the information.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget control number.

Dated: January 16, 1997.

Ada E. Deer,

Assistant Secretary—Indian Affairs.

[FR Doc. 97-3103 Filed 2-6-97; 8:45 am]

BILLING CODE 4310-02-P